BRCA2 and breast cancer: Consistent with our finding in PDAC, a publicly available database for Genomics of Drug Sensitivity in Cancer [19] revealed that PARP inhibitors and BET inhibitors (e.g., JQ1, PFI-1, I-BET-762) are preferentially cytotoxic in mutant BRCA2 context in breast cancer and pan-cancer, respectively (Fig. 2F, G).